Lucidas (Dasatinib 20mg)

Lucidas (Dasatinib) 20mg is a kinase inhibitor indicated for the treatment of

1. newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.

2. adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.

3. adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.

4. pediatric patients with Ph+ CML in chronic phase

Dasatinib DOSAGE

1. Chronic phase CML in adults: 100 mg once daily.

2. Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults: 140 mg once daily.

3. Chronic phase CML in pediatrics: starting dose based on body weight.

4. Administer orally, with or without a meal. Do not crush, cut, or chew tablets.

Dasatinib PI

For more Prescribing information，please check the → “FDA Prescribing Information”.